Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Mini-Review Article

Falcipain-2 and Falcipain-3 Inhibitors as Promising Antimalarial Agents

Author(s): Roberta Ettari*, Santo Previti, Carla Di Chio and Maria Zappalà

Volume 28, Issue 15, 2021

Published on: 30 July, 2020

Page: [3010 - 3031] Pages: 22

DOI: 10.2174/0929867327666200730215316

Price: $65

Abstract

Malaria remains a serious problem in global public health, particularly widespread in South America and in tropical regions of Africa and Asia. Chemotherapy is actually the only way to treat this poverty-related disease, since an effective vaccine is not currently available. However, the onset of resistance to the most common antimalarial drugs sometimes makes the current therapeutic regimen problematic. Therefore, the identification of new targets for a new drug discovery process is an urgent priority. In this context, falcipain-2 and falcipain- 3 of P. falciparum represent the key enzymes in the life-cycle of the parasite. Both falcipain- 2 and falcipain-3 are involved in hemoglobin hydrolysis, an essential pathway to provide free amino acids for the parasite metabolic needs. In addition, falcipain-2 is involved in cleaving ankirin and band 4.1 protein, which are cytoskeletal elements essential for the stability of the red cell membrane. This review article is focused on the most recent and effective inhibitors of falcipain-2 and falcipain-3, with particular attention to peptide, peptidomimetic or nonpeptide inhibitors, which targeted one or both the malarial cysteine proteases, endowed with a consistent activity against P. falciparum.

Keywords: Falcipain-2, falcipain-3, malaria, Plasmodium falciparum, cysteine protease inhibitors, therapeutics.

« Previous Next »
[1]
WHO, The "World malaria report 2019" at a glance. Available at: https://www.who.int/news-room/feature-stories/detail/world-malaria-report-2019 [accessed on: April 15th 2021].
[2]
WHO, Emergency response to artemisinin resistance in the Greater Mekong subregion. Regional framework for action 2013-2015 (archived). Available at: https://www.who.int/malaria/publications/atoz/9789241505321/en/ [accessed on: April 15th 2021].
[3]
Ettari, R.; Bova, F.; Zappalà, M.; Grasso, S.; Micale, N. Falcipain-2 inhibitors. Med. Res. Rev., 2010, 30(1), 136-167.
[http://dx.doi.org/10.1002/med.20163] [PMID: 19526594]
[4]
Liu, J.; Istvan, E.S.; Gluzman, I.Y.; Gross, J.; Goldberg, D.E. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proc. Natl. Acad. Sci. USA, 2006, 103(23), 8840-8845.
[http://dx.doi.org/10.1073/pnas.0601876103] [PMID: 16731623]
[5]
Sherman, I.W.; Tanigoshi, L. Incorporation of 14C-amino-acids by malaria (Plasmodium lophurae) IV.in vivo utilization of host cell haemoglobin. Int. J. Biochem., 1970, 1(5), 635-637.
[http://dx.doi.org/10.1016/0020-711X(70)90033-9]
[6]
Sherman, I.W. Amino acid metabolism and protein synthesis in malarial parasites. Bull. World Health Organ., 1977, 55(2-3), 265-276.
[PMID: 338183]
[7]
Greenbaum, D.C.; Baruch, A.; Grainger, M.; Bozdech, Z.; Medzihradszky, K.F.; Engel, J.; DeRisi, J.; Holder, A.A.; Bogyo, M. A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science, 2002, 298(5600), 2002-2006.
[http://dx.doi.org/10.1126/science.1077426] [PMID: 12471262]
[8]
Shenai, B.R.; Sijwali, P.S.; Singh, A.; Rosenthal, P.J. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J. Biol. Chem., 2000, 275(37), 29000-29010.
[http://dx.doi.org/10.1074/jbc.M004459200] [PMID: 10887194]
[9]
Ramjee, M.K.; Flinn, N.S.; Pemberton, T.P.; Quibell, M.; Wang, Y.; Watts, J.P. Substrate mapping and inhibitor profiling of falcipain-2, falcipain-3 and berghepain-2: implications for peptidase anti-malarial drug discovery. Biochem. J., 2006, 399(1), 47-57.
[http://dx.doi.org/10.1042/BJ20060422] [PMID: 16776649]
[10]
Hanspal, M.; Dua, M.; Takakuwa, Y.; Chishti, A.H.; Mizuno, A. Plasmodium falciparum cysteine protease falcipain-2 cleaves erythrocyte membrane skeletal proteins at late stages of parasite development. Blood, 2002, 100(3), 1048-1054.
[http://dx.doi.org/10.1182/blood-2002-01-0101] [PMID: 12130521]
[11]
Dahl, E.L.; Rosenthal, P.J. Biosynthesis, localization, and processing of falcipain cysteine proteases of Plasmodium falciparum. Mol. Biochem. Parasitol., 2005, 139(2), 205-212.
[http://dx.doi.org/10.1016/j.molbiopara.2004.11.009] [PMID: 15664655]
[12]
Wang, S.X.; Pandey, K.C.; Somoza, J.R.; Sijwali, P.S.; Kortemme, T.; Brinen, L.S.; Fletterick, R.J.; Rosenthal, P.J.; McKerrow, J.H. Structural basis for unique mechanisms of folding and hemoglobin binding by a malarial protease. Proc. Natl. Acad. Sci. USA, 2006, 103(31), 11503-11508.
[http://dx.doi.org/10.1073/pnas.0600489103] [PMID: 16864794]
[13]
Kerr, I.D.; Lee, J.H.; Pandey, K.C.; Harrison, A.; Sajid, M.; Rosenthal, P.J.; Brinen, L.S. Structures of falcipain-2 and falcipain-3 bound to small molecule inhibitors: implications for substrate specificity. J. Med. Chem., 2009, 52(3), 852-857.
[http://dx.doi.org/10.1021/jm8013663] [PMID: 19128015]
[14]
Machin, J.M.; Kantsadi, A.L.; Vakonakis, I. The complex of Plasmodium falciparum falcipain-2 protease with an (E)-chalcone-based inhibitor highlights a novel, small, molecule-binding site. Malar. J., 2019, 18(1), 388-388.
[http://dx.doi.org/10.1186/s12936-019-3043-0] [PMID: 31791339]
[15]
Hogg, T.; Nagarajan, K.; Herzberg, S.; Chen, L.; Shen, X.; Jiang, H.; Wecke, M.; Blohmke, C.; Hilgenfeld, R.; Schmidt, C.L. Structural and functional characterization of Falcipain-2, a hemoglobinase from the malarial parasite Plasmodium falciparum. J. Biol. Chem., 2006, 281(35), 25425-25437.
[http://dx.doi.org/10.1074/jbc.M603776200] [PMID: 16777845]
[16]
Kerr, I.D.; Lee, J.H.; Farady, C.J.; Marion, R.; Rickert, M.; Sajid, M.; Pandey, K.C.; Caffrey, C.R.; Legac, J.; Hansell, E.; McKerrow, J.H.; Craik, C.S.; Rosenthal, P.J.; Brinen, L.S. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J. Biol. Chem., 2009, 284(38), 25697-25703.
[http://dx.doi.org/10.1074/jbc.M109.014340] [PMID: 19620707]
[17]
Pandey, K.C.; Wang, S.X.; Sijwali, P.S.; Lau, A.L.; McKerrow, J.H.; Rosenthal, P.J. The Plasmodium falciparum cysteine protease falcipain-2 captures its substrate, hemoglobin, via a unique motif. Proc. Natl. Acad. Sci. USA, 2005, 102(26), 9138-9143.
[http://dx.doi.org/10.1073/pnas.0502368102] [PMID: 15964982]
[18]
Sijwali, P.S.; Shenai, B.R.; Rosenthal, P.J. Folding of the Plasmodium falciparum cysteine protease falcipain-2 is mediated by a chaperone-like peptide and not the prodomain. J. Biol. Chem., 2002, 277(17), 14910-14915.
[http://dx.doi.org/10.1074/jbc.M109680200] [PMID: 11827964]
[19]
Rosenthal, P.J. Falcipain cysteine proteases of malaria parasites: an update. Biochim. Biophys. Acta. Proteins Proteomics, 2020, 1868(3), 140362.
[http://dx.doi.org/10.1016/j.bbapap.2020.140362] [PMID: 31927030]
[20]
Rosenthal, P.J.; McKerrow, J.H.; Aikawa, M.; Nagasawa, H.; Leech, J.H. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J. Clin. Invest., 1988, 82(5), 1560-1566.
[http://dx.doi.org/10.1172/JCI113766] [PMID: 3053784]
[21]
Rosenthal, P.J.; Wollish, W.S.; Palmer, J.T.; Rasnick, D. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J. Clin. Invest., 1991, 88(5), 1467-1472.
[http://dx.doi.org/10.1172/JCI115456] [PMID: 1939639]
[22]
Rosenthal, P.J.; Lee, G.K.; Smith, R.E. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Invest., 1993, 91(3), 1052-1056.
[http://dx.doi.org/10.1172/JCI116262] [PMID: 8450035]
[23]
Rosenthal, P.J.; Olson, J.E.; Lee, G.K.; Palmer, J.T.; Klaus, J.L.; Rasnick, D. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob. Agents Chemother., 1996, 40(7), 1600-1603.
[http://dx.doi.org/10.1128/AAC.40.7.1600] [PMID: 8807047]
[24]
Olson, J.E.; Lee, G.K.; Semenov, A.; Rosenthal, P.J. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg. Med. Chem., 1999, 7(4), 633-638.
[http://dx.doi.org/10.1016/S0968-0896(99)00004-8] [PMID: 10353642]
[25]
Lee, B.J.; Singh, A.; Chiang, P.; Kemp, S.J.; Goldman, E.A.; Weinhouse, M.I.; Vlasuk, G.P.; Rosenthal, P.J. Antimalarial activities of novel synthetic cysteine protease inhibitors. Antimicrob. Agents Chemother., 2003, 47(12), 3810-3814.
[http://dx.doi.org/10.1128/AAC.47.12.3810-3814.2003] [PMID: 14638488]
[26]
Chakka, S.K.; Kalamuddin, M.; Sundararaman, S.; Wei, L.; Mundra, S.; Mahesh, R.; Malhotra, P.; Mohmmed, A.; Kotra, L.P. Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents. Bioorg. Med. Chem., 2015, 23(9), 2221-2240.
[http://dx.doi.org/10.1016/j.bmc.2015.02.062] [PMID: 25840796]
[27]
Singh, A.; Shenai, B.R.; Choe, Y.; Gut, J.; Sijwali, P.S.; Craik, C.S.; Rosenthal, P.J. Critical role of amino acid 23 in mediating activity and specificity of vinckepain-2, a papain-family cysteine protease of rodent malaria parasites. Biochem. J., 2002, 368(Pt 1), 273-281.
[http://dx.doi.org/10.1042/bj20020753] [PMID: 12169096]
[28]
Nizi, E.; Sferrazza, A.; Fabbrini, D.; Nardi, V.; Andreini, M.; Graziani, R.; Gennari, N.; Bresciani, A.; Paonessa, G.; Harper, S. Peptidomimetic nitrile inhibitors of malarial protease falcipain-2 with high selectivity against human cathepsins. Bioorg. Med. Chem. Lett., 2018, 28(9), 1540-1544.
[http://dx.doi.org/10.1016/j.bmcl.2018.03.069] [PMID: 29615344]
[29]
Coterón, J.M.; Catterick, D.; Castro, J.; Chaparro, M.J.; Díaz, B.; Fernández, E.; Ferrer, S.; Gamo, F.J.; Gordo, M.; Gut, J.; de las Heras, L.; Legac, J.; Marco, M.; Miguel, J.; Muñoz, V.; Porras, E.; de la Rosa, J.C.; Ruiz, J.R.; Sandoval, E.; Ventosa, P.; Rosenthal, P.J.; Fiandor, J.M. Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. J. Med. Chem., 2010, 53(16), 6129-6152.
[http://dx.doi.org/10.1021/jm100556b] [PMID: 20672841]
[30]
Ang, K.K.; Ratnam, J.; Gut, J.; Legac, J.; Hansell, E.; Mackey, Z.B.; Skrzypczynska, K.M.; Debnath, A.; Engel, J.C.; Rosenthal, P.J.; McKerrow, J.H.; Arkin, M.R.; Renslo, A.R. Mining a cathepsin inhibitor library for new antiparasitic drug leads. PLoS Negl. Trop. Dis., 2011, 5(5), e1023.
[http://dx.doi.org/10.1371/journal.pntd.0001023] [PMID: 21572521]
[31]
Royo, S.; Schirmeister, T.; Kaiser, M.; Jung, S.; Rodríguez, S.; Bautista, J.M.; González, F.V. Antiprotozoal and cysteine proteases inhibitory activity of dipeptidyl enoates. Bioorg. Med. Chem., 2018, 26(16), 4624-4634.
[http://dx.doi.org/10.1016/j.bmc.2018.07.015] [PMID: 30037754]
[32]
Weldon, D.J.; Shah, F.; Chittiboyina, A.G.; Sheri, A.; Chada, R.R.; Gut, J.; Rosenthal, P.J.; Shivakumar, D.; Sherman, W.; Desai, P.; Jung, J.C.; Avery, M.A. Synthesis, biological evaluation, hydration site thermodynamics, and chemical reactivity analysis of α-keto substituted peptidomimetics for the inhibition of Plasmodium falciparum. Bioorg. Med. Chem. Lett., 2014, 24(5), 1274-1279.
[http://dx.doi.org/10.1016/j.bmcl.2014.01.062] [PMID: 24507921]
[33]
Stolze, S.C.; Deu, E.; Kaschani, F.; Li, N.; Florea, B.I.; Richau, K.H.; Colby, T.; van der Hoorn, R.A.L.; Overkleeft, H.S.; Bogyo, M.; Kaiser, M. The antimalarial natural product symplostatin 4 is a nanomolar inhibitor of the food vacuole falcipains. Chem. Biol., 2012, 19(12), 1546-1555.
[http://dx.doi.org/10.1016/j.chembiol.2012.09.020] [PMID: 23261598]
[34]
Conroy, T.; Guo, J.T.; Hunt, N.H.; Payne, R.J. Total synthesis and antimalarial activity of symplostatin 4. Org. Lett., 2010, 12(23), 5576-5579.
[http://dx.doi.org/10.1021/ol1024663] [PMID: 21049908]
[35]
Conroy, T.; Guo, J.T.; Elias, N.; Cergol, K.M.; Gut, J.; Legac, J.; Khatoon, L.; Liu, Y.; McGowan, S.; Rosenthal, P.J.; Hunt, N.H.; Payne, R.J. Synthesis of gallinamide A analogues as potent falcipain inhibitors and antimalarials. J. Med. Chem., 2014, 57(24), 10557-10563.
[http://dx.doi.org/10.1021/jm501439w] [PMID: 25412465]
[36]
Stoye, A.; Juillard, A.; Tang, A.H.; Legac, J.; Gut, J.; White, K.L.; Charman, S.A.; Rosenthal, P.J.; Grau, G.E.R.; Hunt, N.H.; Payne, R.J. Falcipain inhibitors based on the natural product gallinamide A are potent in vitro andin vivo antimalarials. J. Med. Chem., 2019, 62(11), 5562-5578.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00504] [PMID: 31062592]
[37]
Previti, S.; Ettari, R.; Cosconati, S.; Amendola, G.; Chouchene, K.; Wagner, A.; Hellmich, U.A.; Ulrich, K.; Krauth-Siegel, R.L.; Wich, P.R.; Schmid, I.; Schirmeister, T.; Gut, J.; Rosenthal, P.J.; Grasso, S.; Zappalà, M. Development of novel peptide-based michael acceptors targeting rhodesain and falcipain-2 for the treatment of neglected tropical diseases (NTDs). J. Med. Chem., 2017, 60(16), 6911-6923.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00405] [PMID: 28763614]
[38]
Ettari, R.; Pinto, A.; Previti, S.; Tamborini, L.; Angelo, I.C.; La Pietra, V.; Marinelli, L.; Novellino, E.; Schirmeister, T.; Zappalà, M.; Grasso, S.; De Micheli, C.; Conti, P. Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation. Bioorg. Med. Chem., 2015, 23(21), 7053-7060.
[http://dx.doi.org/10.1016/j.bmc.2015.09.029] [PMID: 26432608]
[39]
Adessi, C.; Soto, C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem., 2002, 9(9), 963-978.
[http://dx.doi.org/10.2174/0929867024606731] [PMID: 11966456]
[40]
Werner, H.M.; Cabalteja, C.C.; Horne, W.S. Peptide backbone composition and protease susceptibility: impact of modification type, position, and tandem substitution. ChemBioChem, 2016, 17(8), 712-718.
[http://dx.doi.org/10.1002/cbic.201500312] [PMID: 26205791]
[41]
Lauffer, D.J.; Mullican, M.D. A practical synthesis of (S) 3-tert-butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydro-1,5-benzodiazepine-1-acetic acid methyl ester as a conformationally restricted dipeptido-mimetic for caspase-1 (ICE) inhibitors. Bioorg. Med. Chem. Lett., 2002, 12(8), 1225-1227.
[http://dx.doi.org/10.1016/S0960-894X(02)00107-5] [PMID: 11934593]
[42]
Micale, N.; Kozikowski, A.P.; Ettari, R.; Grasso, S.; Zappalà, M.; Jeong, J.J.; Kumar, A.; Hanspal, M.; Chishti, A.H. Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents. J. Med. Chem., 2006, 49(11), 3064-3067.
[http://dx.doi.org/10.1021/jm060405f] [PMID: 16722625]
[43]
Ettari, R.; Nizi, E.; Di Francesco, M.E.; Dude, M.A.; Pradel, G.; Vicík, R.; Schirmeister, T.; Micale, N.; Grasso, S.; Zappalà, M. Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors. J. Med. Chem., 2008, 51(4), 988-996.
[http://dx.doi.org/10.1021/jm701141u] [PMID: 18232656]
[44]
Ettari, R.; Nizi, E.; Di Francesco, M.E.; Micale, N.; Grasso, S.; Zappalà, M.; Vicík, R.; Schirmeister, T. Nonpeptidic vinyl and allyl phosphonates as falcipain-2 inhibitors. ChemMedChem, 2008, 3(7), 1030-1033.
[http://dx.doi.org/10.1002/cmdc.200800050] [PMID: 18428116]
[45]
Ettari, R.; Micale, N.; Schirmeister, T.; Gelhaus, C.; Leippe, M.; Nizi, E.; Di Francesco, M.E.; Grasso, S.; Zappalà, M. Novel peptidomimetics containing a vinyl ester moiety as highly potent and selective falcipain-2 inhibitors. J. Med. Chem., 2009, 52(7), 2157-2160.
[http://dx.doi.org/10.1021/jm900047j] [PMID: 19296600]
[46]
Ettari, R.; Zappalà, M.; Micale, N.; Schirmeister, T.; Gelhaus, C.; Leippe, M.; Evers, A.; Grasso, S. Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain. Eur. J. Med. Chem., 2010, 45(7), 3228-3233.
[http://dx.doi.org/10.1016/j.ejmech.2010.04.003] [PMID: 20434817]
[47]
Ettari, R.; Zappalà, M.; Micale, N.; Grazioso, G.; Giofrè, S.; Schirmeister, T.; Grasso, S. Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors. Eur. J. Med. Chem., 2011, 46(6), 2058-2065.
[http://dx.doi.org/10.1016/j.ejmech.2011.02.058] [PMID: 21420760]
[48]
Ettari, R.; Micale, N.; Grazioso, G.; Bova, F.; Schirmeister, T.; Grasso, S.; Zappalà, M. Synthesis and molecular modeling studies of derivatives of a highly potent peptidomimetic vinyl ester as falcipain-2 inhibitors. ChemMedChem, 2012, 7(9), 1594-1600.
[http://dx.doi.org/10.1002/cmdc.201200274] [PMID: 22753258]
[49]
Shenai, B.R.; Lee, B.J.; Alvarez-Hernandez, A.; Chong, P.Y.; Emal, C.D.; Neitz, R.J.; Roush, W.R.; Rosenthal, P.J. Structure-activity relationships for inhibition of cysteine protease activity and development of Plasmodium falciparum by peptidyl vinyl sulfones. Antimicrob. Agents Chemother., 2003, 47(1), 154-160.
[http://dx.doi.org/10.1128/AAC.47.1.154-160.2003] [PMID: 12499184]
[50]
Ettari, R.; Tamborini, L.; Angelo, I.C.; Grasso, S.; Schirmeister, T.; Lo Presti, L.; De Micheli, C.; Pinto, A.; Conti, P. Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead. ChemMedChem, 2013, 8(12), 2070-2076.
[http://dx.doi.org/10.1002/cmdc.201300390] [PMID: 24243827]
[51]
Ettari, R.; Previti, S.; Cosconati, S.; Kesselring, J.; Schirmeister, T.; Grasso, S.; Zappalà, M. Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors. J. Enzyme Inhib. Med. Chem., 2016, 31(6), 1184-1191.
[http://dx.doi.org/10.3109/14756366.2015.1108972] [PMID: 26572904]
[52]
Ettari, R.; Pinto, A.; Tamborini, L.; Angelo, I.C.; Grasso, S.; Zappalà, M.; Capodicasa, N.; Yzeiraj, L.; Gruber, E.; Aminake, M.N.; Pradel, G.; Schirmeister, T.; De Micheli, C.; Conti, P. Synthesis and biological evaluation of papain-family cathepsin L-like cysteine protease inhibitors containing a 1,4-benzodiazepine scaffold as antiprotozoal agents. ChemMedChem, 2014, 9(8), 1817-1825.
[http://dx.doi.org/10.1002/cmdc.201402079] [PMID: 24919925]
[53]
Schmidt, I.; Pradel, G.; Sologub, L.; Golzmann, A.; Ngwa, C.J.; Kucharski, A.; Schirmeister, T.; Holzgrabe, U. Bistacrine derivatives as new potent antimalarials. Bioorg. Med. Chem., 2016, 24(16), 3636-3642.
[http://dx.doi.org/10.1016/j.bmc.2016.06.003] [PMID: 27316542]
[54]
Knapp, M.J.; Knopman, D.S.; Solomon, P.R.; Pendlebury, W.W.; Davis, C.S.; Gracon, S.I. The Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA, 1994, 271(13), 985-991.
[http://dx.doi.org/10.1001/jama.1994.03510370037029] [PMID: 8139083]
[55]
Bell, A.; Wernli, B.; Franklin, R.M. Effects of microtubule inhibitors on protein synthesis in Plasmodium falciparum. Parasitol. Res., 1993, 79(2), 146-152.
[http://dx.doi.org/10.1007/BF00932261] [PMID: 8475033]
[56]
Sharma, K.; Shrivastava, A.; Mehra, R.N.; Deora, G.S.; Alam, M.M.; Zaman, M.S.; Akhter, M. Synthesis of novel benzimidazole acrylonitriles for inhibition of Plasmodium falciparum growth by dual target inhibition. Arch. Pharm. (Weinheim), 2018, 351(1), 1700251.
[http://dx.doi.org/10.1002/ardp.201700251] [PMID: 29227011]
[57]
Singh, A.K.; Rajendran, V.; Pant, A.; Ghosh, P.C.; Singh, N.; Latha, N.; Garg, S.; Pandey, K.C.; Singh, B.K.; Rathi, B. Design, synthesis and biological evaluation of functionalized phthalimides: a new class of antimalarials and inhibitors of falcipain-2, a major hemoglobinase of malaria parasite. Bioorg. Med. Chem., 2015, 23(8), 1817-1827.
[http://dx.doi.org/10.1016/j.bmc.2015.02.029] [PMID: 25766631]
[58]
Chen, M.; Theander, T.G.; Christensen, S.B.; Hviid, L.; Zhai, L.; Kharazmi, A. Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob. Agents Chemother., 1994, 38(7), 1470-1475.
[http://dx.doi.org/10.1128/AAC.38.7.1470] [PMID: 7979274]
[59]
Belluti, F.; Uliassi, E.; Veronesi, G.; Bergamini, C.; Kaiser, M.; Brun, R.; Viola, A.; Fato, R.; Michels, P.A.; Krauth-Siegel, R.L.; Cavalli, A.; Bolognesi, M.L. Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. ChemMedChem, 2014, 9(2), 371-382.
[http://dx.doi.org/10.1002/cmdc.201300399] [PMID: 24403089]
[60]
Lamb, K.M. G-Dayanandan, N.; Wright, D.L.; Anderson, A.C. Elucidating features that drive the design of selective antifolates using crystal structures of human dihydrofolate reductase. Biochemistry, 2013, 52(41), 7318-7326.
[http://dx.doi.org/10.1021/bi400852h] [PMID: 24053334]
[61]
Barnett, D.S.; Guy, R.K. Antimalarials in development in 2014. Chem. Rev., 2014, 114(22), 11221-11241.
[http://dx.doi.org/10.1021/cr500543f] [PMID: 25340626]
[62]
Huang, H.; Lu, W.; Li, X.; Cong, X.; Ma, H.; Liu, X.; Zhang, Y.; Che, P.; Ma, R.; Li, H.; Shen, X.; Jiang, H.; Huang, J.; Zhu, J. Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent. Bioorg. Med. Chem. Lett., 2012, 22(2), 958-962.
[http://dx.doi.org/10.1016/j.bmcl.2011.12.011] [PMID: 22192590]
[63]
Chen, W.; Huang, Z.; Wang, W.; Mao, F.; Guan, L.; Tang, Y.; Jiang, H.; Li, J.; Huang, J.; Jiang, L.; Zhu, J. Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely. Bioorg. Med. Chem., 2017, 25(24), 6467-6478.
[http://dx.doi.org/10.1016/j.bmc.2017.10.017] [PMID: 29111368]
[64]
Nzila, A.; Rottmann, M.; Chitnumsub, P.; Kiara, S.M.; Kamchonwongpaisan, S.; Maneeruttanarungroj, C.; Taweechai, S.; Yeung, B.K.; Goh, A.; Lakshminarayana, S.B.; Zou, B.; Wong, J.; Ma, N.L.; Weaver, M.; Keller, T.H.; Dartois, V.; Wittlin, S.; Brun, R.; Yuthavong, Y.; Diagana, T.T. Preclinical evaluation of the antifolate QN254, 5-chloro- N’6′-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate. Antimicrob. Agents Chemother., 2010, 54(6), 2603-2610.
[http://dx.doi.org/10.1128/AAC.01526-09] [PMID: 20350951]
[65]
Dheer, D.; Singh, V.; Shankar, R. Medicinal attributes of 1,2,3-triazoles: current developments. Bioorg. Chem., 2017, 71, 30-54.
[http://dx.doi.org/10.1016/j.bioorg.2017.01.010] [PMID: 28126288]
[66]
Chu, X.M.; Wang, C.; Wang, W.L.; Liang, L.L.; Liu, W.; Gong, K.K.; Sun, K.L. Triazole derivatives and their antiplasmodial and antimalarial activities. Eur. J. Med. Chem., 2019, 166, 206-223.
[http://dx.doi.org/10.1016/j.ejmech.2019.01.047] [PMID: 30711831]
[67]
Shah, F.; Wu, Y.; Gut, J.; Pedduri, Y.; Legac, J.; Rosenthal, P.J.; Avery, M.A. Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors. MedChemComm, 2011, 2(12), 1201-1207.
[http://dx.doi.org/10.1039/c1md00129a]
[68]
Singh, A.; Kalamuddin, M.; Mohmmed, A.; Malhotra, P.; Hoda, N. Quinoline-triazole hybrids inhibit falcipain-2 and arrest the development of Plasmodium falciparum at the trophozoite stage. RSC Advances, 2019, 9(67), 39410-39421.
[http://dx.doi.org/10.1039/C9RA06571G]
[69]
Rana, D.; Kalamuddin, M.; Sundriyal, S.; Jaiswal, V.; Sharma, G.; Das Sarma, K.; Sijwali, P.S.; Mohmmed, A.; Malhotra, P.; Mahindroo, N. Identification of antimalarial leads with dual falcipain-2 and falcipain-3 inhibitory activity. Bioorg. Med. Chem., 2020, 28(1), 115155.
[http://dx.doi.org/10.1016/j.bmc.2019.115155] [PMID: 31744777]
[70]
Shah, F.; Mukherjee, P.; Gut, J.; Legac, J.; Rosenthal, P.J.; Tekwani, B.L.; Avery, M.A. Identification of novel malarial cysteine protease inhibitors using structure-based virtual screening of a focused cysteine protease inhibitor library. J. Chem. Inf. Model., 2011, 51(4), 852-864.
[http://dx.doi.org/10.1021/ci200029y] [PMID: 21428453]
[71]
Ciapetti, P.; Giethlen, B. Chapter 15- Molecular variation based on isosteric replacements. In:The Practice of Medicinal Chemistry, 3rd ed; Wermuth, C.G., Ed.; Elsevier: Amsterdam, 2008.
[http://dx.doi.org/10.1016/B978-0-12-374194-3.00015-9]
[72]
Shah, F.; Wu, Y.; Gut, J.; Pedduri, Y.; Legac, J.; Rosenthal, P.J.; Avery, M.A. Design, synthesis and biological avaluation of novel benzothiazole and triazole analogs as falcipain inhibitors. Med. Chem., 2011, 2, 1201-1207.
[http://dx.doi.org/10.1039/C1MD00129A]
[73]
Hasne, M.; Barrett, M.P. Drug uptake via nutrient transporters in Trypanosoma brucei. J. Appl. Microbiol., 2000, 89(4), 697-701.
[http://dx.doi.org/10.1046/j.1365-2672.2000.01168.x] [PMID: 11054175]
[74]
Landfear, S.M. Drugs and transporters in kinetoplastid protozoa. Adv. Exp. Med. Biol., 2008, 625, 22-32.
[http://dx.doi.org/10.1007/978-0-387-77570-8_3] [PMID: 18365656]
[75]
Santos-Magalhães, N.S.; Mosqueira, V.C. Nanotechnology applied to the treatment of malaria. Adv. Drug Deliv. Rev., 2010, 62(4-5), 560-575.
[http://dx.doi.org/10.1016/j.addr.2009.11.024] [PMID: 19914313]
[76]
Torchilin, V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev., 2006, 58(14), 1532-1555.
[http://dx.doi.org/10.1016/j.addr.2006.09.009] [PMID: 17092599]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy